Category: Epidiolex

cannabidiol, Cannabis Industry & Marijuana Business Briefs, cbd, Dravet syndrome, Epidiolex, Europe Cannabis Industry & Marijuana Business News, FDA, GW Pharmaceuticals, International Marijuana Business News, Lennox-Gastaut syndrome, Medical Cannabis Industry & Recreational Marijuana Business News, tuberous sclerosis complex, U.S. Food and Drug Administration, United States Cannabis Industry & Marijuana Business News

FDA approves GW Pharmaceuticals’ cannabis drug for new indication

CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a third medical condition, expanding […]

agreement, analysis, analytics, Aussie, Australia, Australian, British, business, Business Analysis, CANADA, canadian, cannabinoid, cannabis, cbd, clinic, compliance, consumer, cooperation, cultivation, drug, England, Epidiolex, EU, europe, European, export, Federal, firm, German, Germany, global, government, growing, GW Pharma, GW Pharmaceuticals, healthcare, hospital, import, industry, insurance, insure, international, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, network, NHS, patient, pharmacies, pharmacy, pool, prescribe, prescription, producer, product, production, Quality, regulation, regulations, regulatory, retail, Sativex, state, thc, THC Global, UK, union, United Kingdom, wide, world

Will Australia’s Cannabis Program Follow Canada’s Lead?

Will Australia’s Cannabis Program Follow Canada’s Lead?

The news is intriguing in a world overwhelmed with pandemic news. THC Global, a Canadian-Aussie company now raising money and signing global […]